-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-03-27
Values as of: 2024-03-27
The investment seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index measures the performance of the healthcare providers sector of the U.S. equity market. The fund may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Company Website : www.ishares.com
Currency: USD
Country : USA
Inception Date: 01/05/2006
Primary Benchmark: DJ US Select HC Providers TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.44%
Management Expense Ratio: 0.43 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| 3020-OL:HK | X DBMSCIUSA | 9.59 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
+0.04 (+0.03%) |
USD 37.76B |
| VHT | Vanguard Health Care Index Fun.. | 0.10 % |
+0.08 (+0.03%) |
USD 16.98B |
| XBI | SPDR® S&P Biotech ETF | 0.35 % |
+1.27 (+1.54%) |
USD 7.05B |
| IHI | iShares U.S. Medical Devices E.. | 0.43 % |
+0.26 (+0.47%) |
USD 5.55B |
| IXJ | iShares Global Healthcare ETF | 0.46 % |
+0.21 (+0.24%) |
USD 4.11B |
| IYH | iShares U.S. Healthcare ETF | 0.43 % |
-0.07 (-0.12%) |
USD 3.23B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
+0.10 (+0.15%) |
USD 2.94B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.18 (+0.17%) |
USD 1.33B |
| FBT | First Trust NYSE Arca Biotechn.. | 0.57 % |
+1.06 (+0.74%) |
USD 1.08B |
| IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
+0.58 (+0.92%) |
USD 0.69B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| LCR | Leuthold Core ETF | 3.15 % | 0.00 % |
+0.12 (+0.37%) |
USD 0.08B |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.69% | 36% | F | 52% | F | ||
| Dividend Return | 0.20% | 46% | F | 9% | A- | ||
| Total Return | 3.90% | 36% | F | 49% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 11.44% | 55% | F | 56% | F | ||
| Dividend Return | 0.86% | 47% | F | 9% | A- | ||
| Total Return | 12.30% | 55% | F | 49% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 62.16% | 100% | F | 76% | C+ | ||
| Dividend Return | 4.33% | 68% | D+ | 14% | F | ||
| Total Return | 66.48% | 95% | A | 73% | C | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 10.63% | 100% | F | 74% | C | ||
| Dividend Return | 11.21% | 100% | F | 71% | C- | ||
| Total Return | 0.58% | 60% | D- | 15% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 16.12% | 55% | F | 66% | D+ | ||
| Risk Adjusted Return | 69.56% | 73% | C | 92% | A | ||
| Market Capitalization | 0.52B | 55% | F | 53% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
